Such novel serum biomarkers as matrix metalloprotease 9 (MMP-9), pentraxin 3, growth differentiation factor 15 (GDF-15), myeloperoxidase (MPO) and monocyte chemoattractant protein 1 (MCP-1) were proved to increase CAD risk prediction in a general population. This evidence concerns the gene MPO and coronary artery disorder.